scispace - formally typeset
D

Daniela Taverna

Researcher at University of Turin

Publications -  95
Citations -  4700

Daniela Taverna is an academic researcher from University of Turin. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 35, co-authored 84 publications receiving 4222 citations. Previous affiliations of Daniela Taverna include Howard Hughes Medical Institute & Novartis.

Papers
More filters
Journal ArticleDOI

Enhanced Pathological Angiogenesis in Mice Lacking beta3 Integrin or beta3 and beta5 Integrins

TL;DR: It is reported that mice lacking β3Integrins or both β3 and β5 integrins not only support tumorigenesis, but have enhanced tumor growth as well and the tumors in these integrin-deficient mice display enhanced angiogenesis, strongly suggesting that neither β3 nor β5integrins are essential for neovascularization.
Journal ArticleDOI

Urinary exosomal microRNAs in incipient diabetic nephropathy.

TL;DR: In this article, the miRNA expression in urinary exosomes from type 1 diabetic patients with and without incipient diabetic nephropathy was assessed and miR-145 levels were increased and this was paralleled by miR145 overexpression within the glomeruli.
Journal ArticleDOI

microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C

TL;DR: Using a melanoma progression model, a novel pathway controlled by miR‐214 that coordinates metastatic capability is identified and a critical role for this miRNA in disease progression and the establishment of distant metastases is suggested.
Journal ArticleDOI

microRNA-222 Controls Neovascularization by Regulating Signal Transducer and Activator of Transcription 5A Expression

TL;DR: Investigating the potential contribution of microRNAs to inflammation-mediated neovessel formation identified STAT5A as a novel miR-222 target, and this finding opens up new perspectives for treatment of vascular diseases.
Journal Article

Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells.

TL;DR: The data indicate that the expression of c-erbB-2 is repressed during estrogen-induced proliferation and enhanced during growth arrest and/or differentiation of mammary cells.